Some CFTR correctors, like those approved for the treatment of the ΔF508 mutation in cystic fibrosis (VX661, VX445, and VX809), exert their action as true pharmacological chaperones, which bind and stabilize the mutated CFTR. Here, CFTR is linked to cystic fibrosis.